The Latest Cardiac and Vascular News
GENEVA, March 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus […]
PHILADELPHIA, March 15, 2023 /PRNewswire/ — Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry, today announced Rod MacKenzie CMG, PhD. as their new Chairman of the Board of Directors. “I am excited to join the team at Clario,” said Dr. MacKenzie. “The company […]
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid […]
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing deals Potential U.S. market approval for Maxigesic® IV in H2 2023 Promising new product candidates driving innovation and on track for a planned acceleration towards a portfolio of 30 assets before 2025 Revenues of €3 million, net […]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc., a private medical device company that has developed the Globe® PF System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first patients have been successfully treated in its PULSAR clinical study. The international, multicenter study recently received U.S. Food and […]
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial […]
A cash position of more than €20 million at the end of 2022, which provides the Company financial visibility until the end of the first half of 2024; A decisive year on the clinical front with the results of the Phase II/III REVERSE-IT study on TOTUM•63, expected before the end […]
DUBLIN–(BUSINESS WIRE)–FIRE1, today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates and Seventure Partners. The financing provides FIRE1 […]
Dr. Frank J. Veith and McDermott + Bull Partner Ken Dropiewski talk about the challenges in getting the medical field to adopt new procedures, the state of the vascular techniques he introduced to the industry, as well as an insider’s look into the field with his new book, The Medical […]
Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially […]
